Clinical Trials Browser

Withdrawn × INDUSTRY × Hematologic Neoplasms × Clear all

Hematologic Neoplasms

NCT05061654 2023-08-14

CEF-10

Phase 4 Withdrawn

Classical hematologyOther hematologic neoplasm

Hematologic Neoplasms, Febrile Neutropenia

NCT01792882 2023-02-28

GBCPRT0008

Withdrawn

BreastGastrointestinalGenitourinaryOther hematologic neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT04464889 2021-10-08

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02487459 2020-10-05

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02709993 2019-10-14

Consolidation Therapy in Patients With Hematologic Malignancies

Phase 1/2 Withdrawn

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Phase 2 Withdrawn

Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

NCT02223312 2018-08-28

Therapy for Progressive and/or Refractory Hematologic Malignancies

Phase 1/2 Withdrawn

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT01554254 2016-08-31

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Phase 2 Withdrawn

OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882374 2016-08-31

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Phase 2 Withdrawn

OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2 Withdrawn

OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

NCT01168882 2012-08-02

Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies

Phase 1 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT01445587 2012-03-26

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Phase 2 Withdrawn

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Hematologic Neoplasms

Clinical Trials

ARIA

CEF-10

GBCPRT0008

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Consolidation Therapy in Patients With Hematologic Malignancies

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Therapy for Progressive and/or Refractory Hematologic Malignancies

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma